Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma-Reference-Cited by-同舟云学术

Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma

Published:2022-04-11 Issue:6 Volume:101 Page:1211-1216
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Hatano Kaoru,Fujiwara Shin-ichiro,Umino Kento,Ikeda Takashi,Nakano Hirofumi,Mashima Kiyomi,Kawaguchi Shin-ichiro,Ito Shoko,Toda Yumiko,Nagayama Takashi,Minakata Daisuke,Yamasaki Ryoko,Morita Kaoru,Yamamoto Chihiro,Ashizawa Masahiro,Sato Kazuya,Ueda Masuzu,Ohmine Ken,Kanda Yoshinobu^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-022-04832-9.pdf

Reference14 articles.

1. Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1–12

2. Nakade S, Ohno T, Kitagawa J et al (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63:75–83

3. McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17–24

4. Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184–4190

5. Assouline S, Meyer RM, Infante-Rivard C et al (2007) Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leuk Lymphoma 48:513–520

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?;Journal of Clinical Medicine;2023-11-15

2. Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study;BMJ Supportive & Palliative Care;2023-03-16